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Treatment of elevated serum phosphorus in hemodialysis
patients remains challenging due in part to the lack of a
well-tolerated, safe, and effective phosphate binder. Here
we report the results of a single-center, open-label, phase I
clinical trial of 44 hemodialysis patients to show the safety
and efficacy of a novel iron-based phosphate binder, SBR759.
After establishing its safety at an initial dose of 3.75g/day,
SBR759 was given to successive cohorts in several divided
doses of up to 22.5 g/day. The defined measure of efficacy
was the average change in serum phosphorus in the cohorts
receiving 11.25 and 15.0g/day, in whom the mean reduction
was 2.1mg/dl. A clinically and statistically significant
reduction in serum phosphorus was found across the entire
dose range. All patients were able to achieve mean
phosphorus levels within K/DOQI target ranges at the end of
the first week. SBR759 was well tolerated within the
anticipated clinical dose range of 3.75–15g/day. No
treatment-related serious adverse events were observed nor
were there clinically relevant changes in iron indices. While
these preliminary studies highlight the clinical efficiency and
safety of SBR759, its promise of improved therapeutic
options for hyperphosphatemia in patients with chronic
kidney disease requires further study.
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Experimental and observational studies suggest serum
phosphorus (P) may be a novel, modifiable risk factor for
cardiovascular disease, particularly in patients with chronic
kidney disease (CKD).1–3 As a result, national and inter-
national guidelines addressing the treatment of mineral
metabolism in this population suggest that elevations in
serum P be treated with dietary P restriction, provision of
adequate renal replacement therapy, and/or the use of
phosphate binding medication (phosphate binders, PBs).4
All PBs have a similar mechanism of action; binding to
available P in the small intestine thereby limiting its systemic
absorption. The primary discriminating feature of widely
prescribed PBs is the presence or absence of calcium.
Aluminum (Al)-containing PBs were used until the early
1980s when it was reported that the absorption of Al was
associated with progressive dementia, erythropoietin-resis-
tant anemia, and osteomalacia.5,6 Calcium-containing PBs
(CCPBs) quickly replaced Al PBs and were the only available
option until 1998 when the first non-calcium, non-Al PB
were introduced.7,8
Over the last decade considerable controversy has arisen as
to whether the increased calcium ‘load’ associated with the
use of CCPBs is associated with any adverse clinical
outcomes. Several reports have indicated that progression
of vascular calcification is attenuated with the use of the non-
calcium PB, sevelamer hydrochloride and at least one
prospective observational study suggests that progressive
increases in vascular calcification are associated with
increased mortality.9–11 Two reports describe an increased
mortality associated with the use of CCPB or increased
calcium load.11,12 However, one large clinical trial found no
increase in the risk of death in prevalent hemodialysis
patients receiving CCPB.13
Despite the availability of both calcium and non-calcium
PBs, achievement of target serum P levels remains frustra-
tingly difficult with nearly 50% of all patients with end-stage
renal disease not achieving internationally recommended
levels.14 Among the many obstacles to successful control of
serum P with PBs, pill burden, product formulation (tablet/
capsule size in particular), and tolerability have a consider-
able role. As a result, clinicians recognize the large unmet
need that exists for PBs with unique formulations that reduce
pill burden while maximizing safety and tolerability.
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The primary objective of this clinical trial was to
document the safety, tolerability, and efficacy of a novel,
non-calcium, non-Al PB, SBR759, in patients with hyperpho-
sphatemia receiving hemodialysis. SBR759 is a unique,
polymeric complex composed of iron (III) and starch that
has been formulated as a neutral, nearly tasteless, odorless
powder. It has been shown to be an effective PB in vivo and
shows rapid, selective, and tight in vitro binding of phosphate
at both highly acidic and neutral pH with phosphate-binding
capacity similar to currently available agents.15,16 In this
study, we determined that SBR759 was both effective and well
tolerated at doses up to 15 g/day.
RESULTS
Patient disposition is shown in Figure 1. Forty-four patients
received at least one dose of SBR759 and 39 patients
completed 4 weeks of treatment. Reasons for discontinuation
included adverse events (AEs) in three subjects (one in the
3.75 g/day cohort and two in the 22.5 g/day cohort) and
failure to comply with study procedures in two subjects.
Forty-four subjects met the a priori definition for inclusion in
the safety and intention to treat (ITT) analysis populations
whereas 30 met the definition of the pharmacodynamic (PD)
population. Demographic characteristics were well balanced
between treatment cohorts as shown in Table 1.
Primary efficacy results
In the ITT population, a clinically and statistically significant
reduction in serum P was measured from end of washout to
end of treatment across the dose range of 3.75 g to 22.5 g/day
as shown in Figure 2. All treatment cohorts were able to
achieve mean P levels within Kidney Disease Outcomes
Quality Initiative (K/DOQI) defined targets at the end of
week 1.
Changes in serum P for the PD population are presented
in Table 2. There was a clear, rapid, dose response during the
first 2 weeks of treatment. The primary efficacy analysis was
based on the 11.25 and 15.0 g/day cohorts in whom the mean
reduction in serum P was 2.13±0.17mg/dl (P¼ 0.002 for a
reduction larger than 1.5mg/dl) at the end of treatment.
Screened (N=69)
Enrolled (N=60)
Screen failures (N=9)
• PTH  650 pg/ml (N=2)
• Phosphorus  6.0 mg/dl (N=2)
• Phosphorus  3.0 mg/dl (N =1)
• Renal transplant (N =1)
• Use of anti-seizure medication (N =1)
• Illegal drug use (N =1)
• Withdrew consent (N=1)
Washout failures (N =15)
•Serum phosphorus values did not increase to
> 5.5 mg/dl (low stratum) or > 6.0 mg/dl (high
stratum) (N=12)
Death (N =1)
Randomized (N=44)
Cardiopulmonary arrest secondary to asthma
exacerbation. Occurred during run-in phase.
• Adverse events during run-in phase (N=2)
•Consent withdrawn (N =1)
Cohort 2Cohort 1 Cohort 3 Cohort 4 Cohort 5
7.5 g/day3.75 g/day 11.25 g/day 15 g/day 22.5 g/day
Treated (N =10)Treated (N =10) Treated (N =10) Treated (N =10) Treated (N=4)
Completed (N =10)Completed (N=9) Completed (N =9) Completed (N =10) Completed (N =1)
Discontinued (N=1)Discontinued (N=1) Discontinued (N=3)
Figure 1 |Patient disposition.
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Each of the five treatment groups had relatively consistent
dietary intake values across visits. Table 3 provides the
absolute dietary intake values of total energy (Kcal), protein
(g), phosphorus (mg), calcium (mg) and iron (mg), and
shows that there were no meaningful trends among these
dietary components suggesting that food intake did not
contribute to the observed effect on serum P. Furthermore,
there was no significant change in dialysis adequacy (urea
reduction ratio ) and/or the normalized protein catabolic rate
during the study, suggesting that neither changes in dialysis
efficiency nor overall protein intake could account for
observed changes in serum P.
Adverse events
SBR759 was safe and well tolerated at doses up to 15 g/day for
4 weeks. Among all cohorts, 189 AEs were reported during
the study, approximately 50% of which was reported
during the run-in and washout phases (before subjects were
receiving SBR759). Ninety-seven AEs were reported by 36 of
44 subjects receiving SBR759. AEs were primarily localized to
the gastrointestinal (GI) tract with the three most frequent
AEs being discolored feces (10/20 subjects in stratum I, 10/24
subjects in stratum II), diarrhea (4/20 subjects in stratum
I and 9/24 subjects in stratum II), and hypocalcemia
(1/20 subjects in stratum I, 5/24 subjects in stratum II).
The highest dose, 22.5 g/day, was designed to test the safety
and tolerability of a supratherapeutic dose of SBR75, and as
expected, AEs were more common in this cohort. Within the
expected clinical dose range (3.75–15 g/day), the three most
common AEs remained discolored feces (19/40), diarrhea
(11/40), and hypocalcemia (6/40) as shown in Table 4. Only
six of the hypocalcemic events were considered to be AEs and
four of these were mild, one was moderate, and one was
considered severe. One of these subjects had undergone
parathyroidectomy 4 months previously and the others re-
main with asymptomatic serum calcium values o8.4mg/dl.
Fifteen subjects in this trial were supplemented with nightly
calcium; however, only the aforementioned two subjects
received greater than 800mg per night.
Fifteen percent of patients in both strata reported diarrhea
before exposure to SBR759. In the high-dose strata all nine
diarrhea cases were reported within 11 days of starting
therapy with the majority (7/9) reported within 3 days. In
five of these nine subjects, diarrhea lasted less than 3 days and
Table 1 | Demographic summary
Stratum I (sevelamer HCl
(or equivalent calcium binder dose)
o7.2 g/day)
Stratum II (sevelamer HCl
(or equivalent calcium binder dose)
X7.2 g/day)
Cohort 1
3.75 g/day (n=10)
Cohort 2
7.5 g/day (n=10)
Cohort 3
11.25g/day (n=10)
Cohort 4
15 g/day (n=10)
Cohort 5
22.5 g/day (n=4)
Not treated
(n=16)
Age (years)
Mean (range) 65 (41–82) 60 (47–72) 59 (39–83) 55 (42–79) 45 (36–62) 60 (39–77)
Gender
Male 5 (50%) 7 (70%) 5 (50%) 3 (30%) 2 (50%) 12 (75%)
Female 5 (50%) 3 (30%) 5 (50%) 7 (70%) 2 (50%) 4 (25%)
ESRD vintage (years)
Mean (range) 5.0 (0.4–15.4) 2.4 (0.5–4.6) 4.5 (2.2–8.7) 3.9 (0.4–7.8) 5.0 (2.5–6.7) 2.7 (0.5–8.0)
Diabetes
Diabetic (%) 60 70 60 50 50 62.5
Abbreviations: ESRD, end-stage renal disease; HCl, hydrochloride.
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Figure 2 | Serum phosphorus by cohort (ITT population).
ITT, intention to treat.
Table 2 | Descriptive statistics for serum phosphorus by
cohort in CKD patients (PD population)
Mean (range) serum phosphorus (mg/dl)
Treatment
(g/day)
End of
washout
End of SBR759
treatment (week 4)
Change
from washout
3.75 (n=6) 6.21 (5.7, 6.7) 4.80 (4.1, 5.6) 1.41 (2.2, 0.2)
7.5 (n=8) 6.43 (5.6, 7.7) 5.24 (4.2, 6.8) 1.19 (2.2, 0.6)
11.25 (n=8) 7.28 (6.3, 9.2) 5.01 (4.2, 6.1) 2.27 (3.2, 1.7)
15 (n=6) 7.49 (6.2, 8.2) 5.55 (4.7, 6.7) 1.94 (3.4, 0.4)
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resolved spontaneously. Two of these nine subjects were in
the 22.5 g/day cohort and for these two subjects treatment
was discontinued due to the severe grade of the AE. Three
serious AEs were reported during or after SBR759 treatment,
including breast cancer, cellulitis, and hypocalcemia. None of
the serious adverse events was considered to be treatment
related. One death occurred in a subject experiencing acute
asthma exacerbation during the run-in phase, before
receiving SBR759.
No meaningful trends were observed in Gastrointestinal
Symptom Rating Scale (GSRS) scores across the treatment
groups before and after SBR759 treatment except that
relatively higher scores were reported at the end of SBR759
treatment in the 22.5 g/day cohort. This was consistent with
the GI intolerance experienced by this abbreviated cohort.
Laboratory values of special interest
Due to the iron component of SBR759, iron indices were
closely monitored during the course of the study. There were
no clinically significant changes in serum ferritin or iron
saturation as shown in Table 5. In addition, there were no
clinically meaningful trends in serum values of glucose, intact
parathyroid hormone (PTH), 25-vitamin D, 1,25-dihydroxy
vitamin D, or low-density lipoprotein cholesterol between
end of washout and end of treatment in any cohort.
DISCUSSION
In this first-in man, phase I clinical trial, SBR759, a novel,
non-calcium, fast-acting, iron (III)- and starch-containing
PB was effective in rapidly reducing serum P and was well
tolerated at doses up to 15 g/day. All treatment cohorts
including the lowest dose cohort (3.75 g/day) achieved
statistically and clinically significant reductions in average
serum P to below K/DOQI defined threshold values within
2 weeks of initiating therapy with SBR759.
SBR759 has several appealing characteristics as a PB. It is a
non-CCPB that, similar to other agents in this class, offers
the ability to control serum P without a direct impact on
calcium balance. This attribute is particularly attractive given
the recent observations of London et al.17 that total daily dose
of calcium is directly correlated to the degree of vascular
calcification in patients with inactive bone. Although the
progression of vascular calcification has only been shown to
be attenuated with the use of the non-calcium PB, sevelamer
hydrochloride, the use of non-CCPBs may have a significant
Table 3 | Daily intake of dietary components by treatment group
Treatment group Dietary component Baseline End of washout phase
End of SBR759
treatment phase
3.75 g/day Food energy (kcals), (mean, s.d.) 1230 (643.4) 911.3 (368.8) 860.4 (436)
Protein (g), (mean, s.d.) 46.6 (22.9) 33.7 (17.2) 29.1 (20)
Phosphorus (mg), (mean, s.d.) 748.8 (371.3) 529.8 (243.2) 463.8 (262.3)
Calcium (mg), (mean, s.d.) 429.6 (230.1) 248.8 (134.1) 233.4 (142.7)
Iron (mg), (mean, s.d.) 10.1 (5.2) 7.0 (4.1) 5.3 (2.6)
7.5 g/day Food energy (kcals), (mean, s.d.) 1622.4 (690.8) 1398.4 (545.3) 1305.8 (523.5)
Protein (g), (mean, s.d.) 59.9 (26.4) 54.3 (20.5) 50.2 (24.1)
Phosphorus (mg), (mean, s.d.) 889.0 (417.6) 827.1 (333.1) 794.3 (364.7)
Calcium (mg), (mean, s.d.) 470.6 (234.1) 457.6 (206.8) 465.5 (212.7)
Iron (mg), (mean, s.d.) 10.9 (4.9) 9.2 (3.5) 9.0 (4.0)
11.25 g/day Food energy (kcals), (mean, s.d.) 1389.6 (727.3) 1245.0 (595.1) 979.7 (425.3)
Protein (g), (mean, s.d.) 50.9 (23.1) 45.9 (20.9) 39.1 (14.9)
Phosphorus (mg), (mean, s.d.) 773.9 (350.2) 764.4 (408.9) 593.2 (238.4)
Calcium (mg), (mean, s.d.) 397.1 (206.8) 480.7 (319.3) 353.6 (174.2)
Iron (mg), (mean, s.d.) 9.2 (4.3) 8.2 (4.1) 6.5 (2.4)
15 g/day Food energy (kcals), (mean, s.d.) 1806.4 (600.5) 1273.9 (350.2) 1383.0 (587.2)
Protein (g), (mean, s.d.) 68.6 (27.5) 46.4 (12.7) 52.1 (28.7)
Phosphorus (mg), (mean, s.d.) 1091.9 (466.2) 759.5 (271.6) 867.8 (531)
Calcium (mg), (mean, s.d.) 625.6 (284.3) 473.7 (240.8) 818.0 (576.2)
Iron (mg), (mean, s.d.) 13.7 (6.5) 9.2 (3.6) 9.4 (4.5)
22.5 g/day Food energy (kcals), (mean, s.d.) 1315.0 (401.5) 1369.8 (414.7) 1415.1 (495)
Protein (g), (mean, s.d.) 49.2 (14.7) 50.3 (14.7) 52.0 (28.3)
Phosphorus (mg), (mean, s.d.) 844.7 (321.9) 818.5 (347.4) 818.0 (576.2)
Calcium (mg), (mean, s.d.) 612.6 (305.4) 572.5 (331.4) 631.9 (547.7)
Iron (mg), (mean, s.d.) 10.2 (4.0) 9.4 (4.3) 9.5 (7.0)
Table 4 | Summary of adverse events (cohorts 1–4)
Event
Run-in/
washout
phase (n=44)
Cohort 1
(n=10)
Cohort 2
(n=10)
Cohort 3
(n=10)
Cohort 4
(n=10)
Constipation 2 1
Diarrhea 7 3 1 2 5
Discolored feces 1 7 3 5 4
Nausea 4 2
Vomiting 3 2
Upper respiratory
tract infection
3
Hypocalcemia 4 1 2 3
Hypoglycemia 3
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therapeutic advantage in patients who are known to show
vascular calcification as it is expected that the calcium load
associated with CCPBs may directly suppress PTH and thus
indirectly lead to low turnover bone disease. Indeed a recent
report in patients with CKD stage 4 and 5 and 5D describes
that progression of vascular calcification and total daily
elemental calcium load were independently predictive of
mortality.11 In addition, public presentations of new inter-
national guidelines for the management of CKD-Mineral and
Bone Disorder recommend restricting the use of CCPBs in
patients with CKD who are known to have vascular
calcification.18
Numerous recent observational studies have reported that
serum P above 3.5mg/dl is associated with decreased survival
even in patients with no evidence of CKD.2,19 In support of
these observations, investigators have recently reported that
serum P43.9mg/dl is associated with an increased athero-
sclerotic burden as shown by computed tomography calcium
scores in community-dwelling young adults.3 Together these
data suggest that phosphate lowering into the mid-normal
range may be desirable not only in subjects with CKD but
perhaps in those in the general population at high risk of
cardiovascular disease. The availability of safe, effective, well-
tolerated PBs that are unlikely to contribute directly or
indirectly to progression of vascular calcification will greatly
facilitate the ability to test this hypothesis in randomized
controlled clinical trials.
Two additional favorable characteristics of SBR759 deserve
mention. First, this is the first PB to be developed primarily
in a powder formulation. Each unit administration, regard-
less of dose, was administered in a simple 30–60 cc admixture
with water or room temperature non-carbonated, non-acidic
juice. The maximal total amount of fluid required for
administration of SBR759 was 180 cc/day and this fluid was
typically part of the patients’ usual fluid intake rather than
additional fluid. There was no change in the average
interdialytic weight gain and there were no AEs related to
excessive fluid gain. Many subjects in this trial showed a clear
and consistent preference for this delivery approach, a
finding not unexpected given the very large total pill burden
placed on these individuals. Indeed, clinically effective doses
of alternative PBs are typically in the range of 9 pills per day,
although recent reports do suggest that serum P can be
managed effectively with lanthanum carbonate in doses of 3
pills per day in a fraction of patients receiving hemodialysis.20
Although the powder formulation of SBR759 is certainly a
desirable characteristic and is a potential advantage of this
compound, prospective comparisons of this formulation to
other currently available formulations are warranted to
substantiate this potential advantage.
The second characteristic is that the accompanying cation
in SBR759 is iron. Oral iron salts have an extensively reported
safety and tolerability profile in subjects with or without
CKD and in fact, was recommended to patients with CKD as
a standard of care before the widespread availability of
injectable iron. In the SBR759 compound, iron is present as
ferric iron(III) that has very low solubility compared to
ferrous iron(II) salts used in oral iron supplements.
Preclinical evidence supports this property inasmuch as less
than 0.2% (0.002) of iron absorption from SBR759 has been
quantified in animals. This is over 100-fold less than the
relative bioavailability of 20–30% (0.2–0.3) for ferrous sulfate.
It is recognized that iron may have a direct effect on
osteoblast function and patients with overt evidence of iron
overload have been shown to have a mineralization defect on
bone biopsy. Although we found no discernible effect on
serum iron indices in this phase 1 trial, formal iron
absorption studies with SBR759 are being considered to
more completely characterize the potential for iron absorp-
tion in man.21
Unlike other iron-based PBs, SBR759 was well tolerated at
all doses tested within the likely therapeutic dose range. Only
patients receiving 22.5 g/day experienced dose-limiting GI
toxicity related to SBR759. Even among this supratherapeutic
dose, one out of three patients completed 4 weeks of
Table 5 | Special clinical laboratory evaluations
Laboratory assessment
Treatment
group (g/day)
End of
washout
End of SBR759
treatment
Ferritin (mg/l) 3.75 335±182 343±193
7.5 252±251 212±194
11.25 226±172 231±132
15 278±182 262±162
22.5 324±292 155±31
Iron saturation (%) 3.75 41±17 33±11
7.5 32±11 35±16
11.25 32±10 36±15
15 33±11 40±11
22.5 35±12 46±27
Glucose (mg/dl) 3.75 101±16 105±23
7.5 195±130 156±78
11.25 143±96 156±115
15 135±66 123±62
22.5 83±14 76±10
nPCR (g/kg/day) 3.75 0.87±0.26 0.83±0.25
7.5 1.03±0.20 0.88±0.13
11.25 0.90±0.15 0.92±0.23
15 1.20±0.42 1.07±0.21
22.5 1.34±0.27 0.97±0.13
iPTH (pg/ml) 3.75 322±188 167±56
7.5 350±196 263±147
11.25 565±264 436±308
15 379±261 360±321
22.5 506±140 437±271
1,25-Dihydroxy
vitamin D (pg/ml)
3.75 16±15 11±8
7.5 10±7 15±13
11.25 10±12 18±12
15 10±8 10±7
22.5 3±4 6±6
25-OH vitamin D
(ng/ml)
3.75 33±21 25±19
7.5 26±9 30±14
11.25 32.7±15 36±19
15 21±8 17±6
22.5 13±10 11±8
Abbreviations: iPTH, intact parathyroid hormone; nPCR, normalized protein
catabolic rate.
Data are mean values±s.d.
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treatment with no AEs and with excellent efficacy. Of course
the GI tolerability will be a primary focus of future clinical
trials in which the dose of SBR759 is titrated to achieve a
specific P level rather than maintained as a fixed dose. In
addition, prospective comparative trials with other PBs will
need to be conducted to more adequately ascertain GI
tolerability.
Somewhat unexpected was the incidence of hypocalcemia
(serum Cao8.4mg/dl). The majority of these events
occurred in subjects with a history of hypocalcemia and
during the transition from calcium-based PBs to SBR759
during the washout phase. Historical serum calcium values
were not used as an inclusion criteria and 70% of subjects
experiencing a calcium o8.4mg/dl in this trial had a history
of this biochemical abnormality. The exact mechanism of
the hypocalcemia is unknown. It remains to be seen if hypo-
calcemia represents a clinically meaningful concern as the
SBR759 program continues to develop.
In conclusion, SBR759 is showed to be an effective and
well-tolerated novel non-CCPB in patients with CKD
receiving hemodialysis. SBR759 has a unique formulation
that is likely to enhance overall compliance and contribute
toward further progress in achieving more appropriate serum
P levels. Of course it must be noted that prospective,
randomized-controlled clinical trials are necessary to deter-
mine the absolute value of SBR759 for the treatment of
hyperphosphatemia in patients with CKD. Despite the active
and engaging controversy concerning the relative risks of
CCPBs, it is accepted by all that there is a great need for
potent, safe, well-tolerated, and cost-effective PBs. SBR759 is
a promising new candidate to improve therapy for hyperpho-
sphatemia in patients with CKD.
MATERIALS AND METHODS
Subjects
Adult (aged 18–85 years) subjects receiving maintenance hemodia-
lysis three times per week were eligible to participate in this trial if
they had controlled serum P (X3 and p6.0mg/dl) for 30 days
before screening and if they were prescribed a constant dose of
sevelamer hydrochloride or CCPB for at least 15 days before the
baseline visit (1st day of run-in period). Subjects were required to
have a PTH level o650 pg/ml, as well as a urea reduction ratio
X65%. In addition, prescribed doses of calcimimetics, vitamin D,
and IV iron were required to remain constant for at least 15 days
before the baseline visit and remain constant during the duration of
the trial. Exclusion criteria included hospitalization within 30 days
before screening, history of a clinically significant GI disorder, major
GI tract surgery, or a history of hemochromatosis. Enrollment began
in February 2007 and continued through January 2008.
Written informed consent was obtained from all subjects before
any study-related procedures were performed and after approval
from the Schulman Institutional Review Board. This clinical trial
was registered with Clinical Trials.Gov (number NCT00750295).
Study design
This was an open-label, single-center, study evaluating the safety,
tolerability, and efficacy of escalating doses of SBR759. The study
schema is shown in Figure 3. Eligible subjects entered a 2-week
run-in period during which they remained on their previously
prescribed PB type and dose (sevelamer hydrochloride and/or
CCPB). After the 2-week run-in period, subjects initiated a 1–2 week
washout period in which their serum P was required to increase to
X5.5mg/dl (low stratum) or X6.0mg/dl (high stratum). Subjects
not meeting inclusion criteria after the washout period were
considered washout failures and were replaced. Subjects were
stratified based on their prestudy PB dose as shown in Table 1.
Eligible subjects (N¼ 44) were assigned to one of five different
SBR759 dose levels (3.75, 7.5, 11.25, 15.0, 22.5 g/day). Subjects in
each of the five cohorts received SBR759 with meals (up to TID) for
4 weeks. SBR759 was provided in premeasured sachets prepared and
packed by Novartis Pharma AG (East Hanover, New Jersey, USA).
Each sachet contained a single dose of 1.25 g. Subjects were
instructed to suspend their SBR759 in approximately 30–60ml of
water, nonacidic juice, or room temperature noncarbonated liquid.
An end of study follow-up evaluation was conducted 4 weeks after
subjects stopped SBR759 treatment.
Dose escalation by cohort occurred sequentially (in 3.75 g
increments up to 15 g/day) only after safety and tolerability were
reviewed by both the sponsor and investigator and after at least six
subjects in a given cohort had been treated for 7 days. Subjects who
experienced a dose-limiting toxicity (diarrheaXgrade 2, abdominal
pain or constipation Xgrade 3, or any other AE of gradeX3
according to the NIH-NCI Common Terminology Criteria for AEs
version 3.0, and suspected to be related to SBR759) during the initial
7 days of treatment were discontinued from the study treatment.
The occurrence of a dose-limiting toxicity inX2 subjects within the
same cohort prompted a review of the safety and tolerability profile
by both the sponsor and investigator to determine whether the
cohort should be terminated, or if dose escalation was permitted.
In addition to dose-limiting toxicities, subjects were discon-
tinued from SBR759 treatment if their serum P exceeded 7mg/dl for
more than 1 week during the treatment period, or if they took less
than 50% of their doses over 1 week, or less than 60% over 2
consecutive weeks. Patient compliance was assessed biweekly by a
medication count determination.
Study procedures
Blood samples were analyzed at Schryver Medical Laboratories
(Denver, CO, USA), Davita Clinical Laboratories (Deland, FL, USA),
and University of Colorado Hospital Laboratory (Denver). Moni-
toring included predialysis measurement of serum P and glucose
three times per week. The urea reduction ratio was performed at five
time points during the study to evaluate the adequacy of dialysis.
Special laboratory assessments were performed to evaluate ferritin,
iron saturation, intact PTH, 1,25-dihydroxy vitamin D, and 25-OH
vitamin D levels.
The self-administered, GSRS was used to evaluate the impact of
treatment-related GI complication(s). The GSRS includes 15 items
divided into 5 subscales (diarrhea, indigestion, abdominal pain, reflux
syndrome, constipation) and uses a seven-grade Likert scale to calculate
the scores (1¼ no discomfort to 7¼ very severe discomfort).
The Block 2005 Food Frequency Questionnaire was completed at
three different time points during the trial (baseline, SBR759
Screening Run-in Washout
Week 4 Week 5 Week 6 Week 7 Week 8 Week 12Week 3Week 2Week 1Week –4 to 0
SBR759 treatment period End oftreatment
Figure 3 | Study schema.
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treatment initiation, and end of treatment) to assess subjects’ dietary
intake and determine specific dietary components (total calories, fat,
protein, iron, and dietary P). Food Frequency Questionnaire
responses were evaluated by NutritionQuest (Berkeley, CA, USA).
In addition, normalized protein catabolic rate was calculated at
various time points during the study to assess adequacy of dietary
protein intake using a kinetic model commonly used in dialysis
patients and in accordance with the recommended National Kidney
Foundation’s K/DOQI Clinical Practice Guidelines.
Statistical and analytical plan
The primary objective of the trial was to assess the safety and
tolerability of escalating doses of SBR759. The primary statistical
end point of the trial was the change in serum P between end of
washout and end of treatment in the PD population. The a priori
defined PD population consisted of subjects within cohorts treated
with 11.25 or 15.0 g/day in whom the end of treatment P was
collected 48 h postdialysis and who were deemed to be compliant
with therapy. For statistical purposes, compliance was defined as
taking at least 60% of scheduled sachets on the day of and on the
2 days preceding the P assessment, as well as taking at least 30% of
scheduled sachets on at least 3 of 4 days before the day of P
assessment.
The study was powered to consider SBR759 clinically active if the
lower limit of the two-sided confidence interval of the mean
decrease from end of washout to end of treatment in these two
cohorts was greater than 1.5mg/dl. The decrease in serum P from
end of washout to end of treatment was modeled by means of an
ANCOVA model adjusted for the serum P at end of washout, the PB
dose before washout, and the SBR759 dose cohort as fixed effects.
This analysis was performed on the PD population from the 11.25
and 15.0 g/day cohorts only.
Analysis of other populations included the ITT population (all
patients that received at least one dose of SBR759) and the safety
population (all patients that received at least one dose of SBR759
and had at least one visit post active treatment).
GSRS data were calculated by averaging the scores of corre-
sponding items by visit separately and summarized by dimension.
Scores in a given dimension were calculated if at least 50% of the
items in that dimension was available at that visit. A total score was
calculated if at least 6 of the 15 items were available at that visit.
Analyses of GSRS scores were conducted on the ITT population
using an ANCOVA model including the stratum, the cohort and the
baseline P level.
Data were entered directly into the study database using single
data entry with electronic verification. The database was locked only
after all queries were resolved. The study was designed by GAB, SB,
and MSP with collaboration from the study sponsor. All analyses
were conducted by Novartis personnel. However the principal
investigator (GAB) had full access to all study data and reports and
had sole responsibility for the article preparation.
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